|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Dengue, an important vector-borne viral disease and one of the most common causes of acute febrile illness (AFI), is considered as a notable public health problem because it spreads rapidly by the bite of infected mosquito and has high incidence of mortality, morbidity and economical challenges associated with it. Bihar, having a population of 104, 099, 452, average annual rainfall of 1,186 mm and having a breeding place for vector Aedes, is prone to dengue outbreaks. Recently, the first dengue vaccine, Dengvaxia (CYD-TDV) has been introduced. Objective of the study is to determine seroprevalence of dengue infection in patients suffering from AFI, seroprevalence of susceptible population and to ascertain whether it is appropriate time to introduce dengue vaccine CYD-TDV to susceptible population. A retrospective cross sectional observational study, of records of all patients of AFI, whose sera was subjected to simultaneous detection of dengue NS1 antigen, anti- dengue IgM and IgG antibody was done from July 2016 to July 2017 at a tertiary care center in eastern India. Out of 384 samples tested, a total of 38 (9. 9%) samples tested positive for dengue infection and the remaining, i.e. 346/384 (90. 20%) were negative and the patients were considered susceptible to dengue infection. The seroprevalence of dengue was high especially in post-monsoon period. Besides continuing preventive and control measures, authorities should consider introduction of the dengue vaccine CYD-TDV.